Abstract

BackgroundIn orthopedic-specific patients, limited evidence exists in regard to prophylactic weight-based enoxaparin dosing in the obese population. We examined the clinical outcomes of administering weight-based enoxaparin to obese orthopedic trauma patients.MethodsThis retrospective study involved 679 patients who underwent orthopedic trauma surgery and were admitted from 1/2016 to 6/2020 at a single institution. Of those patients, 156 patients met our inclusion criteria. Inclusion criteria included BMI>35 kg/m2 and received weight-based enoxaparin post-operatively (defined as any singular dose >40 mg at any time). Blood transfusion, documented hematoma, deep vein thrombosis (DVT), and return visits to the OR after the administration of weight-based enoxaparin were the primary endpoints assessed. Age, BMI, weight, injury severity score (ISS), sex, post-operative time to the first dose of enoxaparin, the total daily dose of enoxaparin, operating room (OR) blood loss, OR time, patient co-morbidities, and pre/post-operative hemoglobin were evaluated for a potential relationship with the primary endpoints.ResultsOne hundred and eighty-five surgeries were performed on a total of 156 patients. Thirty-six of the 185 (19%) surgeries required post-operative blood transfusion after weight-based enoxaparin was given. Higher ISS score, lower pre-operative hemoglobin, and lower post-operative hemoglobin were significant predictors of blood transfusion. Only increased post-operative time to the first dose of enoxaparin was significantly associated with DVT formation. Thirteen of the 156 patients (8.3%) had a post-operative hematoma after administration of enoxaparin, and four of the 13 patients required return to the OR for bleeding complications. ISS was the only significant predictor of post-operative hematoma formation.ConclusionPatients with a higher injury severity score are at an increased risk of adverse bleeding and may benefit from lower doses of enoxaparin administered earlier post-operatively.

Highlights

  • Patients with traumatic injuries and obesity stand out amongst the highest-risk groups of developing venous thromboembolism (VTE) [1-7]

  • BMI, weight, injury severity score (ISS), sex, post-operative time to the first dose of enoxaparin, the total daily dose of enoxaparin, operating room (OR) blood loss, OR time, patient comorbidities, and pre/post-operative hemoglobin were evaluated for a potential relationship with the primary endpoints

  • One hundred and eighty-five surgeries were performed on a total of 156 patients

Read more

Summary

Introduction

Patients with traumatic injuries and obesity stand out amongst the highest-risk groups of developing venous thromboembolism (VTE) [1-7]. Obesity has been shown to be an independent risk factor for VTE in both men and women [8]. Fixed doses of low molecular weight heparin (LMWH) in severely obese patients have higher failure rates of VTE prophylaxis [12]. Anticoagulant-based prophylaxis, including LMWHs, unfractionated heparin, and factor Xa inhibitors, reduces the relative risk of VTE by 45% to 63% in medically-ill patients [14-16]. Studies evaluating LMWH dosing in obese, trauma, and critically ill medical and surgical patients have found a strong negative correlation between weight and anti-Xa levels with fixed dosing and that weight-based dosing results in favorable anti-Xa activity [17-20]. In orthopedic-specific patients, limited evidence exists in regard to prophylactic weight-based enoxaparin dosing in the obese population. We examined the clinical outcomes of administering weight-based enoxaparin to obese orthopedic trauma patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call